Ország: Írország
Nyelv: angol
Forrás: HPRA (Health Products Regulatory Authority)
CEFTAZIDIME PENTAHYDRATE
Martindale Pharmaceuticals Ltd
CEFTAZIDIME PENTAHYDRATE
250 Milligram
Pdr for Soln for Injection
Product subject to prescription which may not be renewed (A)
Withdrawn
0000-00-00
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Ceftazidime 250 mg Powder for solution for injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains 291 mg of ceftazidime pentahydrate, equivalent to 250mg of ceftazidime Excipient: each 250 mg vial of powder contains 30 mg of sodium carbonate This medicinal product contains 0.57 mmol (or 13 mg) of sodium per vial For a full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Powder for solution for injection The powder is white or off-white 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Ceftazidime is indicated for treatment of the following bacterial infections when they are caused by ceftazidime- sensitive bacteria, and only if beta-lactam-antibiotics with a narrower spectrum cannot be used: - Nosocomial pneumonia - Bronchopulmonary infections in cystic fibrosis caused by Pseudomonas aeruginosa - Meningitis caused by aerobic gram-negative microorganisms Consideration should be given to official guidance on the appropriate use of antibacterial agents. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology The dose depends on the degree of severity of the infection, sensitivity and type of infection, and on the age, weight and renal function of the patient. _WITH NORMAL RENAL FUNCTION_ AGE GROUP INFECTION NORMAL DOSE Adults Most indications 1 g every 8 hours (3 g/day) or 2 g every 12 hours (4 g/day) Nosocomial pneumonia and infections in patients with neutropaenia 2 g every 8 hours (6 g/day) Bronchopulmonary infections in cystic fibrosis caused by Pseudomonas aeruginosa 100-150 mg/kg/day, divided into 3 doses; 9 g/day must not be exceeded IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 08/06/2011_ _CRN 2096927_ _page Olvassa el a teljes dokumentumot